Molecular Diagnostics Platform

Antibodies as Biomarkers for Disease

OPKO’s molecular diagnostics platform, developed in the laboratory of Dr. Thomas Kodadek at the Scripps Research Institute, is based on IgG (immunoglobulin G) autoantibodies as disease-specific biomarkers.

In contrast to conventional immunoassay diagnostics, OPKO’s biomarker discovery platform does not require prior knowledge of disease-related antigens.

Molecular Diagnostics Platform

Peptoid probes act as surrogate antigens by capturing disease-specific autoantibodies from diseased patient serum but not healthy patient serum.

Antigen Surrogates as Discovery Tools

Sera from diseased and non-diseased patients are screened against large, diverse libraries of peptoids or other chemical structures that can act as antigen surrogates. These antigen surrogates are then used as probes to capture and identify autoantibody signatures, which are able to differentiate between diseased and normal serum samples.

Once a set of chemical probes have been validated, they can be used in immunoassays on a variety of platforms, including:

  • Microarrays
  • ELISA (enzyme-linked immunosorbent assay)
  • Flow Cytometry

OPKO’s diagnostic discovery and development platform is potentially applicable to: